ERBB2 and breast cancer: The biomolecular stratification of breast cancer is based on the immunohistochemical staining of estrogen receptors, progesterone receptors, human epidermal growth factor receptor 2 (HER2), proliferation marker Ki-67, and, in the case of triple-negative breast cancer, of the programmed death ligand (PDL1).